More than half of patients with advanced ALK-positive lung cancer who started on lorlatinib seven years ago still have not seen their disease worsen, according to a long-term update from the phase 3 CROWN trial published in The Lancet Oncology. The 7-year progression-free survival rate stands at 55% for lorlatinib, while the median time to progression has still not been reached. For a cancer subtype once defined by rapid resistance to targeted drugs, these numbers represent a striking shift in what patients and oncologists can expect from first-line treatment.
Why the CROWN trial’s 7-year lorlatinib data changes the treatment calculus
ALK-positive non-small cell lung cancer accounts for a small but well-defined fraction of all lung cancers. Patients tend to be younger and often non-smokers, but until recently the drugs available to them lost effectiveness within one to two years. Crizotinib, the first ALK inhibitor approved for this population, set a median progression-free survival of just 9.3 months in the comparator arm of the CROWN trial, according to the FDA summary for lorlatinib’s first-line indication. The gap between 9.3 months and a median that remains unreached after seven years is not incremental. It suggests a fundamentally different disease trajectory for patients who start on lorlatinib.
The hypothesis embedded in these results goes beyond survival curves. If most patients on lorlatinib avoid progression for years, they also avoid the cascade of therapy switches, new side-effect profiles, and escalating costs that come with sequential treatment lines. Short-term trial endpoints, which typically capture 12 to 18 months of data, cannot predict whether that cascade is truly averted. Linking CROWN patient identifiers to post-trial claims databases could test whether durable disease control translates into fewer therapy changes and lower cumulative toxicity costs than models built on earlier, shorter follow-up would have predicted. That analysis has not yet been published, but the raw durability of the lorlatinib arm makes it a plausible and testable proposition.
What the CROWN data show at seven years
The CROWN study, registered as NCT03052608, is a randomized, open-label, phase 3 trial comparing first-line lorlatinib against crizotinib in patients with previously untreated advanced ALK-positive NSCLC. The 7-year update, reported in a recent publication, indicates that 55% of patients randomized to lorlatinib remained free of disease progression or death at the seven-year mark. In the crizotinib arm, that figure was 3%. Median progression-free survival in the lorlatinib group has not been reached, a statistical outcome that means more than half of patients on the drug had still not progressed by the time of the data cutoff.
These results did not arrive without precedent within the same trial. An earlier updated analysis, available in respiratory medicine reports, had already shown a widening separation between the two arms at roughly three years of follow-up. What the seven-year data confirm is that the benefit did not erode over time. The separation held steady, and the lorlatinib curve did not show the steep late decline that has historically plagued targeted therapies in this disease.
Overall survival data are still maturing, but the prolonged progression-free interval is clinically meaningful in its own right. For patients, remaining on a single effective oral therapy for many years can translate into stable symptoms, fewer hospitalizations, and the ability to maintain work and family roles. For oncologists, the durability of response changes how they discuss prognosis at diagnosis, shifting conversations from a sequence of inevitable relapses to the possibility of long-term disease control on the first regimen.
The trial’s open-label design means that neither patients nor investigators were blinded to treatment assignment. While this is a recognized limitation, the primary endpoint of progression-free survival was assessed using RECIST criteria, a standardized imaging-based framework that reduces subjective bias in measuring tumor response. Independent radiologic review further mitigates concerns that knowledge of treatment could have skewed assessments. The FDA cited the CROWN results when expanding lorlatinib’s indication to include first-line use in metastatic ALK-positive NSCLC, a regulatory decision that effectively made lorlatinib the standard of care for newly diagnosed patients with this molecular profile.
Another notable feature of the CROWN data set is intracranial efficacy. Many patients with ALK-positive NSCLC either present with, or eventually develop, brain metastases. Lorlatinib was designed with central nervous system penetration in mind, and earlier analyses from CROWN showed high rates of intracranial response and prevention of new brain lesions. The seven-year update suggests that this protection is sustained over time, which may help reduce neurologic complications and the need for radiation or neurosurgical interventions in a population that is otherwise at high risk for CNS progression.
Gaps in the evidence and what to watch next
The 7-year update answers the question of durability but leaves several others open. Patient-level raw data and swimmer plots from the latest data cutoff have not been posted on ClinicalTrials.gov or made available through the brief public summaries. The full article, hosted on the publisher’s platform, contains additional figures and supplementary materials, but granular safety data beyond the earlier three-year analysis have not yet been summarized in FDA materials. Cumulative rates of grade 3 and 4 adverse events over seven years of continuous lorlatinib use remain difficult to assess from publicly available summaries alone.
Neurocognitive effects, lipid abnormalities, and weight gain have been well described with lorlatinib in earlier follow-up, and clinicians have developed routine monitoring and management strategies. What is still unclear is how these toxicities evolve over many years of uninterrupted therapy. Longitudinal quality-of-life measures and detailed reporting on dose reductions or temporary interruptions would help clarify whether patients can sustain treatment without significant functional compromise. Those data will be especially important as more individuals remain on lorlatinib long enough to experience late-onset or cumulative adverse effects.
Real-world outcomes also remain incompletely characterized. The CROWN trial enrolled patients who met specific eligibility criteria, including no prior systemic treatment for advanced disease and adequate organ function. How lorlatinib performs outside those boundaries, in older patients, those with significant comorbidities, or those with brain metastases managed differently than the trial protocol allowed, is not captured in the trial report alone. Observational cohorts and registry-based studies will be needed to determine whether the 7-year progression-free survival seen in CROWN can be reproduced in routine practice.
Another open question is how lorlatinib’s first-line dominance will reshape the treatment landscape for subsequent lines of therapy. Earlier-generation ALK inhibitors such as alectinib, brigatinib, and ceritinib were often used sequentially after crizotinib failure, with each step providing an additional period of disease control. Starting with the most potent agent up front may leave fewer targeted options at progression, particularly if resistance mutations emerge that are not amenable to existing drugs. At the same time, if more than half of patients remain progression-free for seven years or longer, the number who ever need a second ALK inhibitor may fall substantially.
Economic analyses will also evolve in light of the new data. Lorlatinib is an expensive therapy, and early cost-effectiveness models had to extrapolate long-term benefit from relatively short follow-up periods. With seven-year progression-free survival now documented in a randomized trial, those models can be recalibrated using observed rather than assumed durability. Health economists will need to weigh the high upfront drug costs against potential savings from fewer subsequent therapies, reduced hospitalizations, and maintained productivity over a longer horizon, drawing on comparative frameworks such as those used in other targeted oncology settings and described in broader health services analyses.
For now, the CROWN trial’s long-term results solidify lorlatinib as the benchmark for first-line treatment in advanced ALK-positive NSCLC and redefine what long-term control can look like in this molecular subset. The central task ahead is to fill the remaining evidence gaps: detailing long-range safety, understanding real-world performance, and planning for the relatively small but clinically important group of patients who will eventually progress after many years on therapy. As those data emerge, they will determine whether the promise of the seven-year update translates into a durable, system-wide shift in how this form of lung cancer is treated and experienced.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
